Patents by Inventor Yue-Sheng Li

Yue-Sheng Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FGF21 polypeptides comprising two or more mutations
    Patent number: 8034770
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: October 11, 2011
    Assignee: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20110195895
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: October 8, 2009
    Publication date: August 11, 2011
    Applicant: Amgen Inc.
    Inventors: Kenneth W. Walker, Colin V. Gegg, JR., Randy I. Hecht, Edward J. Belousky, Yue-Sheng Li, Mark L. Michaels, Jing Xu, Murielle M. Ellison
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20100285131
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: May 4, 2010
    Publication date: November 11, 2010
    Applicant: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Human anti-IFN-? neutralizing antibodies as selective IFN-? pathway inhibitors
    Patent number: 7790859
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: September 7, 2010
    Assignee: Amgen Inc.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
  • STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF
    Publication number: 20100168020
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Application
    Filed: November 25, 2009
    Publication date: July 1, 2010
    Applicant: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas C. Boone, Rohini Deshpande, Yue-Sheng Li, Hq Han
  • FGF21 Mutants and uses thereof
    Publication number: 20090305986
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: June 3, 2009
    Publication date: December 10, 2009
    Applicant: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Antagonists of the bradykinin B1 receptor
    Publication number: 20090137483
    Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.
    Type: Application
    Filed: April 8, 2008
    Publication date: May 28, 2009
    Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, JR., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
  • Antagonists of the bradykinin B1 receptor
    Publication number: 20090137452
    Abstract: The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.
    Type: Application
    Filed: April 8, 2008
    Publication date: May 28, 2009
    Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, JR., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
  • Antagonists of the bradykinin B1 receptor
    Publication number: 20090048149
    Abstract: The present invention relates to a method of treating, preventing, or ameliorating a disease or condition associated with or mediated by B1 activity that involves administering a composition of matter containing bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. The method can be used therapeutically or prophylactically against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.
    Type: Application
    Filed: April 9, 2008
    Publication date: February 19, 2009
    Inventors: Gordon Ng, Yue-Sheng Li, Colin V. Gegg, Benny C. Askew, JR., Thomas Storz, Yuelie Lu, Derin C. D'Amico, Mark A. Jarosinski, Chuan-Fa Liu, Qi Huang
  • HUMAN ANTI-IFN-GAMMA NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-GAMMA PATHWAY INHIBITORS
    Publication number: 20080107655
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Application
    Filed: December 21, 2007
    Publication date: May 8, 2008
    Applicants: Amgen Inc., Medarex, Inc.
    Inventors: Andrew Welcher, Hilary Chute, Yue-Sheng Li, Haichun Huang
  • Antagonists of the bradykinin B1 receptor
    Publication number: 20050215470
    Abstract: The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.
    Type: Application
    Filed: October 21, 2004
    Publication date: September 29, 2005
    Inventors: Gordon Ng, Yue-Sheng Li, Colin Gegg, Benny Askew, Thomas Storz, Yuelie Lu, Derin D'Amico
  • DNA encoding heparin-binding growth factor
    Patent number: 6448381
    Abstract: A novel heparin-binding growth factor of 18.9 kDa mol. wt. is disclosed which is purified from bovine uterus and human placenta and has a unique 25 N-terminal amino acid sequence as follows: Gly-Lys-Lys-Glu-Lys-Pro-Glu-Lys-Lys-Val-Lys-Lys-Ser-Asp-Cys-Gly-Glu-Trp-Gln-Trp-Ser-Val-Cys-Val-Pro.
    Type: Grant
    Filed: June 21, 1990
    Date of Patent: September 10, 2002
    Assignee: Barnes-Jewish Hospital
    Inventors: Thomas F. Deuel, Yue-Sheng Li, Ned R. Siegel, Peter G. Milner